Sanofi Adds To Vaccine Pipeline With Origimm Acquisition
Austrian Biotech Developing Acne Immunotherapy
As well as buying Origimm, the French giant will also apply its mRNA vaccine platform, acquired through the recent $3.2bn acquisition of Translate Bio, to discover and develop other acne vaccines, aided by the Vienna-headquartered firm's know-how in the field.
